Immunotherapy using CAR T-cells for treating high-risk acute lymphoblastic leukaemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of CD19+CD22 Chimeric Antigen Receptor (CAR) T-cells in children and young adults with high-risk, relapsed acute lymphoblastic leukaemia. Participants will undergo leukapheresis to generate CAR T-cells, followed by lymphodepleting chemotherapy and total body irradiation before receiving the CAR T-cell infusion. The study aims to assess the duration of response and overall efficacy of this innovative immunotherapy approach in a vulnerable patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Children and young adults (age 24 years or younger) with high risk/relapsed CD19+ and CD22+ acute lymphoblastic leukaemia with:

   1. Resistant disease (\>5% blasts) at end of ALLTogether-1 protocol or equivalent induction
   2. ALL with persisting high level MRD at 2nd time point of frontline national protocol (currently MRD \>10-4 at week 9 ALLTogether-1 Protocol or equivalent).
   3. High risk infant ALL (age \< 6 months at diagnosis with MLL gene rearrangement and either presenting white cell count \> 300 x 10\^9/L or poor steroid early response (i.e. circulating blast count \>1x10\^9/L following 7 day steroid pre-phase of induction as per national guidelines or equivalent)
   4. Any patient with t(17,19) TCF3-HLF rearrangement
   5. High risk 1st relapse (defined as very early (relapse within 18 months of diagnosis) and early relapses (any patient relapsing on therapy or within 6 months of completing treatment) and any relapse with high risk genetics, namely (KMT2A (MLL) rearrangements, low hypodiploidy/near haploidy, t(17;19)(q22;p13)/TCF3-HLF, iAMP21 and t(1;19)(q21;p13)/TCF3- PBX1, t(9;22)(34.1 q11.2)/BCR-ABL1
   6. Any on therapy relapse in patients age 16-24
   7. Any relapse of infant ALL
   8. ALL post ≥ 2nd relapse
   9. Any refractory relapse of ALL (defined as \> 1% blasts by flow cytometry after a at least 1 cycle of standard chemotherapy)
   10. ALL with MRD \>10-4 prior to planned stem cell transplant
   11. Any relapse of ALL eligible for stem cell transplant but no available HLA matched donor or other contraindication to transplant
   12. Any relapse of ALL after stem cell transplant as long as planned time of CD19+CD22CAR T cell infusion is \> 4 months post-transplant
   13. Early (defined as \< 6 months post-infusion) loss of B cell aplasia or any CD19+CD22+ relapse following CD19CAR T cell therapy with Tisagenlecleucel

   Note patients with isolated CNS relapse meeting one or more of the criteria above are eligible for the study
2. Agreement to have a pregnancy test, use adequate contraception (if applicable)
3. Written informed consent

Exclusion Criteria:

Exclusion Criteria for registration:

1. Active Hepatitis B, C or HIV infection
2. Oxygen saturation ≤ 90% on air
3. Bilirubin \> 3 x upper limit of normal
4. Creatinine \> 3 x upper limit of normal
5. Women who are pregnant or breastfeeding
6. Stem Cell Transplant patients only: active significant (overall Grade ≥ II, Seattle criteria) acute GVHD or moderate/ severe chronic GVHD (NIH consensus criteria) requiring systemic steroids.
7. Inability to tolerate leucapheresis
8. Karnofsky (age ≥ 10 years) or Lansky (age \< 10) score ≤ 50%
9. Pre-existing significant neurological disorder (other than CNS involvement of underlying haematological malignancy)
10. CD19 negative or CD22 negative disease

Exclusion criteria for CD19+CD22CAR T-cell infusion:

1. Severe intercurrent infection at the time of scheduled CD19+CD22 CAR T-cell infusion
2. Requirement for supplementary oxygen or active pulmonary infiltrates at the time of scheduled CD19+CD22 CAR T-cell infusion
3. Allogeneic transplant recipients with active significant acute GVHD overall grade ≥II or moderate/severe chronic GVHD requiring systemic steroids at the time of scheduled CD19+CD22 CAR T-cell infusion. Note: Such patients will be excluded until the patient is GVHD free and off steroids

Where it's running

• Great Ormond Street Hospital
  London, United Kingdom Recruiting
• University College Hospital
  London, United Kingdom Recruiting
• Manchester Royal Children's Hospital
  Manchester, United Kingdom Recruiting

Study contacts

• Study coordinator: Aniqa Tasnim
• Email: ctc.carpall@ucl.ac.uk
• Phone: 0203 108 4753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• At-home cognitive training and mindfulness for children after CAR-T, transplant, or chemotherapy

  This program tests whether remote digital cognitive exercises combined with adapted mindfulness can help thinking, behavior, and brain function in children and teens treated for acute lymphoblastic leukemia after CAR‑T, chemotherapy, or transplant.

  Recruiting Hospital Universitario La Paz · Madrid, Madrid · NCT07479927

• Using CD22 CAR T-cells to extend remission after commercial CD19 CAR T-cell therapy in children, adolescents, and adults with relapsed/refractory B‑ALL

  This will try giving CD22-targeted CAR T-cells to people aged 3–65 who are in remission after CD19 CAR T-cell therapy to see if it helps keep their B-ALL from coming back longer.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07328503

• CD19 CAR-T consolidation for adolescents and adults with B-ALL who cannot have a transplant

  This treatment tries CD19 CAR-T cell infusions to see if they help adolescents and adults with B-ALL who are unable to get an allogeneic stem cell transplant stay in remission.

  Recruiting at 2 sites Phase 1/2 Zhujiang Hospital · Guangzhou, Guangdong and 1 other locations · NCT07072494

• FIT-CD19 CAR-T (ARM011) therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

  This will test whether a non-viral CD19 CAR-T therapy (ARM011), given after short lymphodepleting chemotherapy, is safe and helps adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 TriArm Therapeutics (Taiwan) Limited · Taipei · NCT07066397

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.